Functional effects of enhancing or silencing adenosine A2b receptors in cardiac fibroblasts.
Cardiac fibroblasts (CF) express adenosine (ADO) receptors, and pharmacological evidence suggests the possible involvement of the A2 (A2a and A2b) receptor (A2aR and A2bR) subtypes in inhibiting cell functions involved in fibrosis. The main objective of this study was to define the contributions of A2a and/or A2b receptors in modulating ADO-induced decreases in CF functions. For this purpose, CF were either treated pharmacologically or had the A2aR or A2bR levels modified through the use of recombinant adenovirus or siRNA. The assessment of mRNA expression in adult rat CF yielded evidence for A1R, A2bR, A2a), and A3R. Endogenously or exogenously enhanced ADO significantly inhibits CF proliferation, collagen, and protein synthesis. A2R and A2aR agonists, although capable of inhibiting CF protein and collagen synthesis, were unable to define the contributions derived from A2aR or A2bR. Overexpression of A2bR in CF yielded significant decreases in basal levels of collagen and protein synthesis and correlated with increases in cAMP levels. However, at higher doses of ADO receptor agonists, significant increases in protein and collagen synthesis were observed. CF with underexpression of A2bR yielded increases in protein and collagen synthesis. In contrast, A2aR underexpression did not modify ADO-induced decreases in CF protein or collagen synthesis. In conclusion, results derived from the molecular manipulation of receptor levels indicate that A2bR are critically involved in ADO-mediated inhibition of CF functions.
University of California at San Diego Medical Center, 200 W. Arbor Dr., San Diego, CA 92103-8412, USA.
Yinghong
Y
Chen
Sara
S
Epperson
Lala
L
Makhsudova
Bruce
B
Ito
Jorge
J
Suarez
Wolfgang
W
Dillmann
Francisco
F
Villarreal
D015762:2-Chloroadenosine / Q000494:pharmacology; D000248:Adenosine Kinase / Q000037:antagonists & inhibitors; D019830:Adenosine-5'-(N-ethylcarboxamide) / Q000494:pharmacology; D000818:Animals; D002455:Cell Division / Q000502:physiology; D002478:Cells, Cultured; D003094:Collagen / Q000096:biosynthesis / Q000378:metabolism; D000242:Cyclic AMP / Q000378:metabolism; D005109:Extracellular Matrix / Q000378:metabolism; D005347:Fibroblasts / Q000166:cytology / Q000378:metabolism*; D015870:Gene Expression; D020868:Gene Silencing; D006352:Heart Ventricles / Q000166:cytology; D007930:Leucine / Q000493:pharmacokinetics; D008297:Male; D009206:Myocardium / Q000166:cytology / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D043705:Receptor, Adenosine A2A / Q000235:genetics / Q000378:metabolism; D043704:Receptor, Adenosine A2B / Q000235:genetics* / Q000378:metabolism*; D013936:Thymidine / Q000493:pharmacokinetics; D014316:Tritium; D014665:Vasodilator Agents / Q000494:pharmacology
D043705:Receptor, Adenosine A2A; D043704:Receptor, Adenosine A2B; D014665:Vasodilator Agents; D014316:Tritium; D015762:2-Chloroadenosine; D019830:Adenosine-5'-(N-ethylcarboxamide); D003094:Collagen; D000242:Cyclic AMP; D000248:Adenosine Kinase; D007930:Leucine; D013936:Thymidine